Skip to main content

Topical Ophthalmic Deal Benchmarks in Ophthalmology

Median Upfront
$491M
Range: $271M - $702M
Total Deal Value
$2.3B
Range: $1.5B - $3.1B
Royalty Rate
8.9% - 17.9%
Tiered up to 21.9%
Dev Milestones
$364M
Range: $246M - $484M
Model Your Deal

Market Analysis

Topical Ophthalmic therapies in ophthalmology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 topical ophthalmic asset in ophthalmology is $491M, with total deal values reaching $2.3B. Development milestones average $364M, while regulatory milestones contribute $455M.

The ophthalmology topical ophthalmic landscape is characterized by moderate competitive intensity concentrated in retinal disease and dry eye. Gene therapies for inherited retinal diseases, extended-duration intravitreal agents, and topical biologics are expanding the opportunity set. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for topical ophthalmic ophthalmology deals range from 8.9% to 17.9% at the base tier, with tiered escalation reaching 12.9%-21.9% on blockbuster sales. Commercial milestones averaging $1.0B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a topical ophthalmic ophthalmology licensing deal?
Based on our analysis, Phase 2 topical ophthalmic licensing deals in ophthalmology average $491M in upfront payments, with a range of $271M to $702M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for topical ophthalmic ophthalmology transactions?
The median total deal value for Phase 2 topical ophthalmic assets in ophthalmology is $2.3B, ranging from $1.5B to $3.1B. This includes development milestones ($364M), regulatory milestones ($455M), and commercial milestones ($1.0B).
What royalty rates are standard for topical ophthalmic deals in ophthalmology?
Base royalty rates for topical ophthalmic ophthalmology transactions range from 8.9% to 17.9%, with tiered escalations reaching 12.9%-21.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in topical ophthalmic ophthalmology deals?
Topical Ophthalmic ophthalmology deals allocate approximately 79% of total deal value to milestones. Development milestones ($364M) make up the largest share, followed by commercial milestones ($1.0B) and regulatory milestones ($455M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Ophthalmology

View

Monoclonal Antibody in Ophthalmology

View

Topical Ophthalmic in Dermatology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included